Black Diamond Therapeutics
BDTX
Market cap $182M

3.22 USD

+0.01

0.31%

Updated Oct 22, 10:47 AM EDT

1 day

0.31%

5 days

-5.57%

1 month

-28.44%

3 months

-45.52%

6 months

-35.86%

Year to date

10.65%

1 year

57.84%

5 years

-91.84%

About: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Employees: 54

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

185% more call options, than puts

Call options by funds: $331K | Put options by funds: $116K

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

9% more capital invested

Capital invested by funds: $199M [Q1] → $217M (+$17.9M) [Q2]

6.86% more ownership

Funds ownership: 75.82% [Q1] → 82.68% (+6.86%) [Q2]

2% more funds holding

Funds holding: 87 [Q1] → 89 (+2) [Q2]

7% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 29

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

242%

upside

Avg. target

$14.11

338%

upside

High target

$20

521%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target	242%upside $11	Buy Reiterated	9 Oct 2024
Wedbush Robert Driscoll 53% 1-year accuracy 26 / 49 met price target	397%upside $16	Outperform Reiterated	8 Oct 2024
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target	242%upside $11	Buy Reiterated	24 Sept 2024
Piper Sandler Joseph Catanzaro 40% 1-year accuracy 8 / 20 met price target	366%upside $15	Overweight Maintained	23 Sept 2024
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target	242%upside $11	Buy Reiterated	18 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about BDTX published over the past 30 days

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic.

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026.

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass.

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Zacks Investment Research

All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy

Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability.

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™